RBC Capital lowered the firm’s price target on Perspective Therapeutics to $27 from $29 and keeps an Outperform rating on the shares. The firm is adjusting its model to further reflect the increased share counts following the reverse split in June, though the company’s Q2 report also contained a notable update to its plan to expand enrollment of VMT-alpha-NET’s Cohort 2 up to 47 patients as the company awaits an alignment with FDA year-end 2024 before opening Cohort 3, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics price target lowered to $17 from $19 at Oppenheimer
- Perspective Therapeutics reports Q2 EPS (18c), consensus (21c)
- Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results
- Options Volatility and Implied Earnings Moves Today, August 12, 2024
- CATX Earnings Report this Week: Is It a Buy, Ahead of Earnings?